CYBB and neoplasm: Unlike the case in these BA-relapsed patients, TIGIT did not appear to be expressed in MCL tumor cells in the BA-refractory patient (R); in contrast, elevated expression of other checkpoint molecules, LAGLS9 and CYBB, was detected in MCL tumor cells from patient R (Supplementary Fig. S5D).